23:09:52 EDT Thu 24 Jun 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Revive Therapeutics Ltd
Symbol RVV
Shares Issued 72,411,282
Close 2020-04-17 C$ 0.125
Recent Sedar Documents

Revive hires Complete Phyto for psilocybin R&D

2020-04-17 08:30 ET - News Release

Mr. Michael Frank reports

REVIVE THERAPEUTICS PARTNERS WITH COMPLETE PHYTOCHEMICAL SOLUTIONS TO ADVANCE RESEARCH INITIATIVES FOR PSILOCYBIN-BASED PHARMACEUTICAL PRODUCTS

Revive Therapeutics Ltd. has engaged Complete Phytochemical Solutions LLC, an internationally recognized company specializing in unique and complex analyses and formulation development of phytochemicals, to advance the company's research and development initiatives of psilocybin-based products for the pharmaceutical market.

"Revive has an intellectual property portfolio of psilocybin-based formulations ready to advance to the next stages of clinical development and with our newly established relationship with Complete Phytochemical Solutions they will bring a wealth of product formulation and testing experience with phytochemicals, including hallucinogenics. Complete Phytochemical Solutions will be instrumental in achieving milestones that will unlock the potential of our psilocybin-based platform," said Michael Frank, Revive's chief executive officer.

"Complete Phytochemical Solutions provides intellectual and technical expertise in phytochemistry that enables our partners to develop, manufacture and market high-quality and efficacious natural products. Revive's investment in research and development of psilocybin-based pharmaceuticals coupled with our state-of-the-art methods for quantification of active compounds will help to ensure that end products are highly standardized," said Christian G. Krueger, Complete Phytochemical Solutions' chief executive officer.

Complete Phytochemical Solutions, formed as a University of Wisconsin-Madison spinoff company in 2010, is led by Christian G. Krueger as chief executive officer and Dr. Jess D. Reed, PhD, as chief scientific officer. Both Dr. Reed and Mr. Krueger conduct translational phytochemical research and formulation development out of the Reed Research Lab at the University of Wisconsin-Madison. Dr. Reed and Mr. Krueger have recently collaborated with Revive on development initiatives using their patented tannin-chitosan composites as a delivery vehicle for cannabinoids.

Revive's psilocybin-based formulations have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. The company has filed key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of psilocybin-based formulations, including sublingual sprays, effervescent tablets, hard-shell capsules, sublingual and transmucosal delivery systems (that is gum drops, oral strips and dosing pens). Furthermore, Revive has a patent-pending methodology that includes psilocybin-based extraction and crystallization methodologies.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the Food and Drug Administration, such as orphan drug, fast-track, breakthrough therapy and rare pediatric disease designations.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.